Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

CardioNet/BioTelemetry Cut By Benjamin J. Taylor’s Hedge Fund

CardioNet/BioTelemetry: CardioNet, Inc. is yet another company that has been recently downsized in the equity portfolio of a hedge fund. According to a filing with the Securities and Exchange Commission, Benjamin J. Taylor‘s hedge fund, Sophrosyne Capital, recently disclosed ownership of around 1.03 million shares of the company, the value of the stake amounting to $9.5 million. In comparison with the stake disclosed in the most recent 13F equity portfolio of Sophrosyne, the hedge fund sold some 907,200 shares.


CardioNet has recently gone through some changes. At the beginning of August a new holding structure became effective, previously approved by its shareholders. In this way, the name CardioNet was switched to BioTelemetry Inc (NASDAQ:BEAT), a name that “more accurately reflects the focus of the organization,” Joseph Capper, President and Chief Executive Officer said in the report of the company’s financial results for the second quarter. The new holding structure of the company was set to improve its growth plan.

Aside from Sophrosyne Capital, we should mention some other hedge funds that disclosed ownership of CardioNet/BioTelemetry at the end of last quarter. Stephen Dubois’s Camber Capital Management disclosed ownership of 1.8 million shares. In second is Trigran Investments, managed by Douglas T. Granat, and Dmitry Balyasny’s Balyasny Asset Management holds 810,200 shares.

Recommended Reading:

Hedge Fund Returns in 2013: The Top 20

Is There Any Value in Bill Ackman’s Holdings?

The Only Warren Buffett Pick Signaling ‘Buy’ Right Now

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!